Design Therapeutics Inc (NASDAQ:DSGN) price on Thursday, March 28, rose 3.07% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $4.03.
A look at the stock’s price movement, the close in the last trading session was $3.91. The beta value (5-Year monthly) was 1.72. Turning to its 52-week performance, $8.47 and $1.94 were the 52-week high and 52-week low respectively. Overall, DSGN moved 41.40% over the past month.
Design Therapeutics Inc’s market cap currently stands at around $227.65 million, with investors looking forward to this quarter’s earnings report slated for May 07, 2024 – May 13, 2024. Analysts project the company’s earnings per share (EPS) to be -$0.27, which has seen fiscal year 2024 EPS growth forecast to increase to -$1.18 and about -$1.36 for fiscal year 2025. Per the data, EPS growth is expected to be 0.80% for 2024 and -15.30% for the next financial year.
Revisions could be used as tool to get short term price movement insight, and for the company that in the past seven days was 2 upward and no downward review(s). Turning to the stock’s technical picture we see that short term indicators suggest on average that DSGN is a 50% Buy. On the other hand, the stock is on average a 50% Buy as suggested by medium term indicators while long term indicators are putting the stock in 50% Buy category.
DSGN’s current price about 35.58% and 50.69% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 74.43, while 7-day volatility ratio is 12.49% and 8.25% in the 30-day chart. Further, Design Therapeutics Inc (DSGN) has a beta value of 1.81, and an average true range (ATR) of 0.25.
If we refocus on Design Therapeutics Inc (NASDAQ:DSGN), historical trading data shows that trading volumes averaged 0.48 million over the past 10 days and 259.38K over the past 3 months. The company’s latest data on shares outstanding shows there are 56.47 million shares.
The 41.87% of Design Therapeutics Inc’s shares are in the hands of company insiders while institutional holders own 44.65% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 2.14 million on Mar 15, 2024, giving us a short ratio of 10.92. The data shows that as of Mar 15, 2024 short interest in Design Therapeutics Inc (DSGN) stood at 3.79% of shares outstanding, with shares short falling to 2.82 million registered in Feb 15, 2024. Current price change has pushed the stock 52.08% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the DSGN stock continues to rise going into the next quarter.